Metabolic MRI with hyperpolarized pyruvate in long-term COVID19 patients

Aarhus University, The MR Research Center0 个研究点目标入组 10 人开始时间: 2021年3月4日最近更新: 2021年5月17日

适应症

试验速览

暂无简介。

•Aged 18 – 85 years.
•Previous COVID-19 confirmed with PCR or antibody test.
•Persistent, post COVID-19 symptoms
•oFrom the brain (fatigue, headache, sensory disturbances or cognitive difficulties) OR
•oFrom the heart (chest pain, dyspnea or tachycardia)
•oSymptoms not explained by other diseases after the extensive work-up at long-term COVID19 clinic.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 8
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2

•Contraindications for MRI with contrast:
•-Chronic kidney disease (eGFR = 30 mL/min/1.73m2)
•-Heart failure with reduced ejection fraction
•-Significant obstructive lung disease or severe asthma
•-Pacemaker, neurostimulator or cholera implant
•-Metal foreign bodies such as fragments and irremovable piercings
•-Unsafe medical implants (safety of heart valves, hips and the like must be confirmed)
•-Intracranial clips or coils
•-Cardiac pacemakers
•-Claustrophobia
•-Largest circumference including arms > 160 cm
•Competing neurological, psychiatric, cardiac, liver or systemic diseases including diabetes (except prior TIA, unspecific brain MRI findings, hypertension, atherosclerosis and hyperlipidemia/cholesterolemia which are allowed)
•Allergy to pyruvate

发起方

Aarhus University, The MR Research Center